The	0	3	O
role	4	8	O
of	9	11	O
organ	12	17	B-Organ
vascularization	18	33	O
and	34	37	O
lipoplex	38	46	B-Drug_or_compound
-	46	47	O
serum	47	52	B-Organism_substance
initial	53	60	O
contact	61	68	O
in	69	71	O
intravenous	72	83	O
murine	84	90	B-Organism
lipofection	91	102	O
.	102	103	O

Following	105	114	O
intravenous	115	126	O
administration	127	141	O
of	142	144	O
cationic	145	153	O
lipid	154	159	O
-	159	160	O
DNA	160	163	O
complexes	164	173	O
(	174	175	O
lipoplexes	175	185	B-Drug_or_compound
)	185	186	O
into	187	191	O
mice	192	196	B-Organism
,	196	197	O
transfection	198	210	O
(	211	212	O
lipofection	212	223	O
)	223	224	O
occurs	225	231	O
predominantly	232	245	O
in	246	248	O
the	249	252	O
lungs	253	258	B-Organ
.	258	259	O

This	260	264	O
was	265	268	O
attributed	269	279	O
to	280	282	O
high	283	287	O
entrapment	288	298	O
of	299	301	O
lipoplexes	302	312	B-Drug_or_compound
in	313	315	O
the	316	319	O
extended	320	328	O
lung	329	333	B-Multi-tissue_structure
vascular	334	342	I-Multi-tissue_structure
tree	343	347	I-Multi-tissue_structure
.	347	348	O

To	349	351	O
determine	352	361	O
whether	362	369	O
lipofection	370	381	O
in	382	384	O
other	385	390	O
organs	391	397	B-Organ
could	398	403	O
be	404	406	O
enhanced	407	415	O
by	416	418	O
increasing	419	429	O
the	430	433	O
degree	434	440	O
of	441	443	O
vascularization	444	459	O
,	459	460	O
we	461	463	O
used	464	468	O
a	469	470	O
transgenic	471	481	O
mouse	482	487	B-Organism
model	488	493	O
with	494	498	O
tissue	499	505	B-Tissue
-	505	506	O
specific	506	514	O
angiogenesis	515	527	O
in	528	530	O
liver	531	536	B-Organ
.	536	537	O

Tail	538	542	B-Multi-tissue_structure
vein	543	547	I-Multi-tissue_structure
injection	548	557	O
of	558	560	O
N	561	562	B-Drug_or_compound
-	562	563	I-Drug_or_compound
(	563	564	I-Drug_or_compound
1	564	565	I-Drug_or_compound
-	565	566	I-Drug_or_compound
(	566	567	I-Drug_or_compound
2	567	568	I-Drug_or_compound
,	568	569	I-Drug_or_compound
3	569	570	I-Drug_or_compound
-	570	571	I-Drug_or_compound
dioleoyloxy	571	582	I-Drug_or_compound
)	582	583	I-Drug_or_compound
propyl	583	589	I-Drug_or_compound
)	589	590	I-Drug_or_compound
-	590	591	I-Drug_or_compound
N	591	592	I-Drug_or_compound
,	592	593	I-Drug_or_compound
N	593	594	I-Drug_or_compound
,	594	595	I-Drug_or_compound
N	595	596	I-Drug_or_compound
-	596	597	I-Drug_or_compound
trimethylammonium	597	614	I-Drug_or_compound
chloride	615	623	I-Drug_or_compound
(	624	625	I-Drug_or_compound
DOTAP	625	630	I-Drug_or_compound
)	630	631	I-Drug_or_compound
/	631	632	I-Drug_or_compound
cholesterol	632	643	I-Drug_or_compound
lipoplexes	644	654	I-Drug_or_compound
resulted	655	663	O
in	664	666	O
increased	667	676	O
lipoplex	677	685	B-Drug_or_compound
entrapment	686	696	O
in	697	699	O
hypervascularized	700	717	O
liver	718	723	B-Organ
but	724	727	O
did	728	731	O
not	732	735	O
boost	736	741	O
luciferase	742	752	B-Gene_or_gene_product
expression	753	763	O
,	763	764	O
suggesting	765	775	O
that	776	780	O
lipoplex	781	789	B-Drug_or_compound
delivery	790	798	O
is	799	801	O
not	802	805	O
a	806	807	O
sufficient	808	818	O
condition	819	828	O
for	829	832	O
efficient	833	842	O
organ	843	848	B-Organ
lipofection	849	860	O
.	860	861	O

Because	862	869	O
the	870	873	O
intravenously	874	887	O
injected	888	896	O
lipoplexes	897	907	B-Drug_or_compound
migrated	908	916	O
within	917	923	O
seconds	924	931	O
to	932	934	O
lungs	935	940	B-Organ
,	940	941	O
we	942	944	O
checked	945	952	O
whether	953	960	O
the	961	964	O
effects	965	972	O
of	973	975	O
immediate	976	985	O
contact	986	993	O
with	994	998	O
serum	999	1004	B-Organism_substance
correlate	1005	1014	O
with	1015	1019	O
lung	1020	1024	B-Organ
lipofection	1025	1036	O
efficiency	1037	1047	O
of	1048	1050	O
different	1051	1060	O
DOTAP	1061	1066	B-Drug_or_compound
-	1066	1067	O
based	1067	1072	O
formulations	1073	1085	O
.	1085	1086	O

Under	1087	1092	O
conditions	1093	1103	O
mimicking	1104	1113	O
the	1114	1117	O
injection	1118	1127	O
environment	1128	1139	O
,	1139	1140	O
the	1141	1144	O
lipoplex	1145	1153	B-Drug_or_compound
-	1153	1154	O
serum	1154	1159	B-Organism_substance
interaction	1160	1171	O
was	1172	1175	O
strongly	1176	1184	O
dependent	1185	1194	O
on	1195	1197	O
helper	1198	1204	O
lipid	1205	1210	B-Drug_or_compound
and	1211	1214	O
ionic	1215	1220	O
strength	1221	1229	O
:	1229	1230	O
lipoplexes	1231	1241	B-Drug_or_compound
prepared	1242	1250	O
in	1251	1253	O
150	1254	1257	O
mM	1258	1260	O
NaCl	1261	1265	O
or	1266	1268	O
lipoplexes	1269	1279	B-Drug_or_compound
with	1280	1284	O
high	1285	1289	O
(	1290	1291	O
greater	1292	1299	O
than	1300	1304	O
33	1305	1307	O
mol	1308	1311	O
%	1311	1312	O
)	1312	1313	O
cholesterol	1314	1325	B-Drug_or_compound
were	1326	1330	O
found	1331	1336	O
to	1337	1339	O
aggregate	1340	1349	O
immediately	1350	1361	O
.	1361	1362	O

This	1363	1367	O
aggregation	1368	1379	O
process	1380	1387	O
was	1388	1391	O
irreversible	1392	1404	O
and	1405	1408	O
was	1409	1412	O
inversely	1413	1422	O
correlated	1423	1433	O
with	1434	1438	O
the	1439	1442	O
percentage	1443	1453	O
of	1454	1456	O
lung	1457	1461	B-Cell
cells	1462	1467	I-Cell
that	1468	1472	O
took	1473	1477	O
up	1478	1480	O
lipoplexes	1481	1491	B-Drug_or_compound
and	1492	1495	O
with	1496	1500	O
the	1501	1504	O
efficiency	1505	1515	O
of	1516	1518	O
lipofection	1519	1530	O
.	1530	1531	O

No	1532	1534	O
other	1535	1540	O
structural	1541	1551	O
changes	1552	1559	O
in	1560	1562	O
serum	1563	1568	B-Organism_substance
were	1569	1573	O
observed	1574	1582	O
for	1583	1586	O
cholesterol	1587	1598	B-Drug_or_compound
-	1598	1599	I-Drug_or_compound
based	1599	1604	I-Drug_or_compound
lipoplexes	1605	1615	I-Drug_or_compound
.	1615	1616	O

Dioleoyl	1617	1625	B-Drug_or_compound
phosphatidylethanolamine	1626	1650	I-Drug_or_compound
-	1650	1651	I-Drug_or_compound
based	1651	1656	I-Drug_or_compound
lipoplexes	1657	1667	I-Drug_or_compound
were	1668	1672	O
found	1673	1678	O
to	1679	1681	O
give	1682	1686	O
low	1687	1690	O
expression	1691	1701	O
,	1701	1702	O
apparently	1703	1713	O
because	1714	1721	O
of	1722	1724	O
an	1725	1727	O
immediate	1728	1737	O
loss	1738	1742	O
of	1743	1745	O
integrity	1746	1755	O
in	1756	1758	O
serum	1759	1764	B-Organism_substance
,	1764	1765	O
without	1766	1773	O
lipid	1774	1779	O
-	1779	1780	O
DNA	1780	1783	O
dissociation	1784	1796	O
.	1796	1797	O

Our	1798	1801	O
study	1802	1807	O
suggests	1808	1816	O
that	1817	1821	O
efficient	1822	1831	O
in	1832	1834	O
vivo	1835	1839	O
lipofection	1840	1851	O
is	1852	1854	O
the	1855	1858	O
result	1859	1865	O
of	1866	1868	O
cross	1869	1874	O
-	1874	1875	O
talk	1875	1879	O
between	1880	1887	O
lipoplex	1888	1896	B-Drug_or_compound
composition	1897	1908	O
,	1908	1909	O
interaction	1910	1921	O
with	1922	1926	O
serum	1927	1932	B-Organism_substance
,	1932	1933	O
hemodynamics	1934	1946	O
,	1946	1947	O
and	1948	1951	O
target	1952	1958	O
tissue	1959	1965	B-Tissue
"	1966	1967	O
susceptibility	1967	1981	O
"	1981	1982	O
to	1983	1985	O
transfection	1986	1998	O
.	1998	1999	O

